Skip to main content

2008 to 2020 Saw Increase in Survival for Advanced Prostate Cancer

Medically reviewed by Drugs.com.

By Lori Solomon HealthDay Reporter

THURSDAY, Oct. 19, 2023 -- During a time period with improvements in treatment of advanced prostate cancer, there was a simultaneous clinically meaningful increase in mean survival for men with de novo metastatic castration-sensitive prostate cancer (mCSPC), according to a study published online Oct. 2 in JAMA Network Open.

Christian Corsini, M.D., from Uppsala University in Sweden, and colleagues examined changes in survival with the introduction of doublet therapy for advanced prostate cancer. The analysis included data from 11,382 men with de novo mCSPC identified in the Prostate Cancer data Base Sweden (2008 to 2020).

The researchers found a shift toward less advanced prostate cancer during the study period with a decrease in median prostate-specific antigen at diagnosis in men with mCSPC from 145 ng/mL to 107 ng/mL. There was an increase seen in upfront treatment with doublet therapy from 1 percent in 2016 to 44 percent in 2020. In addition, there was an increase noted in the adjusted five-year overall survival, from 26 percent in 2008 to 2012 to 35 percent in 2017 to 2020. An increase in mean survival of six months during the first five years after diagnosis was also observed (2.7 years from 2008 to 2012 to 3.2 years from 2017 to 2020).

"Between 2008 and 2020, mean survival increased with six months after five years of follow-up in all individuals with de novo mCSPC, taking changes in age, comorbidity, and cancer characteristics into account, supporting that doublet therapy is effective in clinical practice on a population basis," the authors write.

Abstract/Full Text

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted October 2023

Read this next

New Tool IDs Sexual Struggles in Female Partners of Prostate Cancer Patients

FRIDAY, May 24, 2024 -- The Sexual Concerns In Partners of Patients with Prostate cancer tool is a valid measure of sexual health in female partners of patients with prostate...

Plant-Based Diet May Aid Prostate Cancer Outcomes

FRIDAY, May 3, 2024 -- Consuming a primarily plant-based diet may be associated with better cancer-specific health outcomes among men with prostate cancer, according to a study...

Neoadjuvant Chemohormonal Therapy Aids Locally Advanced Prostate Cancer

THURSDAY, May 2, 2024 -- For patients with locally advanced prostate cancer, neoadjuvant chemohormonal therapy (NCHT) is beneficial for biochemical progression-free survival...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.